[Newsmp] In September, most of the pharmaceutical stocks dropped more than 10% amid repeated lethargy in the pharmaceutical index.
According to the Kore Exchange, the pharmaceutical index has recently fallen to the pre-COVID-19 level, diving to the 12,000-point level.
Of the 46 stocks, 41 companies fell at the end of September from the end of August, and 33 of them recorded double-digit drops.
Among 33 stocks that recorded double-digit drops, 13 stocks declined more than 20%.
The combined market capitalization of 46 stocks was reduced by more than KRW 10 trillion in a month from KRW 123.7 trillion to KRW 112.8 trillion.
By stock, SK Bioscience saw the largest drop of 28.9%, while Shin Poong Pharmaceutical’s also reached 28.8%.
Hanmi Pharmaceutical’s fall exceeded 25% with 25.6%, and Green Cross, Il Dong Pharmaceutical, HanAll Biopharma, CKD Bio, Yungjin Pharm., Samsung Pharmaceutical, PharmGen Science, Il Dong Holdings, Kyongbo Pharmaceutical, and Aprogen Pharmaceuticals also surpassed 20%.
Kukje Pharma, ORIENTBIO, Reyon Pharmaceutical, JW Pharmaceutical, Myungmoon Pharmaceutical, Jeil Pharmaceutical, Pharmicell, Dong Wha Pharm, Il-Yang Pharmaceutical, Bukwang Pharmaceutical, Chong Kun Dang Holdings, Handok, Dongsung Pharmaceutical, Gene One Life Science, Dong-A ST, JW Life Science, Kwang Dong Pharmaceutical, Hana Pharm, and Daewoong Pharmaceutical recorded double-digit drops.
Moreover, stock prices of Hyundai Pharmaceutical, Yuyu Pharma, Chong Kun Dang Pharmaceutical, Celltrion, Daewon Pharmaceutical, Korea United Pharm., Yuhan Corporation, Samsung Biologics, and Whanin Pharmaceutical slid from the end of August.
On the other hand, Ilsung Pharmaceutical’s stock price soared 35.8% despite the bear market, while Samjin Pharmaceutical, Boryung Pharmaceutical, and Samil Pharmaceutical also rose from the end of August.
In the meantime, the market capitalization of SK Bioscience, which once exceeded KRW 25 trillion, has decreased by more than KRW 2.5 trillion over the past month to KRW 6.16 trillion. It has declined to a quarter compared to August last year, which reached KRW 25.66 trillion.
Samsung Biologics and Celltrion’s market capitalization also retreated by nearly KRW 2 trillion last month, and Hanmi Pharmaceutical shrank by about KRW 1 trillion.
The market capitalization of Green Cross and Shin Poong Pharmaceutical sank by more than KRW 400 billion, Ildong Pharmaceutical, HanAll Biopharma, and Daewoong Pharmaceutical by KRW 200 billion, and Daewoong, Yuhan Corporation, Pharmicell, Yungjin Pharm., and Bukwang Pharmaceutical by KRW 100 billion.
At the same time, Ilsung Pharmaceutical, whose share price soared more than 35% in the past month, also saw its market capitalization increase by KRW 75.8 billion, Samjin Pharmaceutical by KRW 20.9 billion, Boryung Pharmaceutical by KRW 17.2 billion, and Samil Pharmaceutical by KRW 1.8 billion.
